Switch Therapeutics has raised a $52M Series A funding round to create therapies for central nervous system diseases.
The company is based in San Francisco.
Switch Therapeutics aims to create therapies for diseases by targeting RNAi activity in specific cell populations based on their internal gene expression.
- Insight Partners and UCB Ventures co-led the funding round, with participation from Eli Lilly and Company, Ono Venture Investment, Digitalis Ventures, Dolby Family Ventures, Free Flow Ventures, and PhiFund Ventures.
- The company aims to use the funding to select and advance a development candidate for its lead program for the treatment of central nervous system diseases.
